Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 3/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.44 |
| ▸ | DAO | P14920 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.44 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALPL | P05186 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL232998 | 0.98 | NR1H2 (0.46) | NR1H2NR1H3DAOTAAR1CALM1 | |
| SCHEMBL5173931 | 0.96 | NR1H2 (0.44) | NR1H2NR1H3DAOTAAR1CALM1 | |
| SCHEMBL11534430 | 0.87 | DAO (0.33) | NR1H2NR1H3DAOTAAR1GAA | |
| SCHEMBL8210477 | 0.87 | NR1H2 (0.45) | NR1H2NR1H3DAOTAAR1NPC1 | |
| SCHEMBL8534048 | 0.83 | GRIN1 (0.52) | — | |
| SCHEMBL9447366 | 0.80 | POLB (0.40) | DAOTAAR1NPC1POLBRAB9A | |
| SCHEMBL4715479 | 0.80 | DAO (0.47) | DAOTAAR1NPC1RAB9AALPL | |
| SCHEMBL4573094 | 0.78 | CYP3A4 (0.48) | GAANPC1POLBRAB9AALDH1A1 | |
| SCHEMBL6505678 | 0.78 | NR1H2 (0.41) | NR1H2DAOPOLBKMT2AALDH1A1 | |
| SCHEMBL18496473 | 0.78 | ESR1 (0.48) | GAAALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2576575-B1 | PROSTAGLANDIN-BISPHOSPHONATE CONJUGATE COMPOUNDS, METHODS OF MAKING SAME, AND USES THEREOF | UNIV FRASER SIMON (CA) | 2018-09-05 | — | — | EP | disclosed |
| US-9611284-B2 | Prostaglandin-bisphosphonate conjugate compounds, methods of making same, and uses thereof | SIMON FRASER UNIVERSITY (CA) | 2017-04-04 | — | — | US | disclosed |
| US-20130157984-A1 | PROSTAGLANDIN-BISPHOSPHONATE CONJUGATE COMPOUNDS, METHODS OF MAKING SAME, AND USES THEREOF | SIMON FRASER UNIVERSITY (CA) | 2013-06-20 | — | — | US | disclosed |
| EP-2576575-A1 | PROSTAGLANDIN-BISPHOSPHONATE CONJUGATE COMPOUNDS, METHODS OF MAKING SAME, AND USES THEREOF | Simon Fraser University (CA) | 2013-04-10 | — | — | EP | disclosed |
| WO-2011147034-A1 | PROSTAGLANDIN-BISPHOSPHONATE CONJUGATE COMPOUNDS, METHODS OF MAKING SAME, AND USES THEREOF | SIMON FRASER UNIVERSITY (CA) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130157984-A1 | PROSTAGLANDIN-BISPHOSPHONATE CONJUGATE COMPOUNDS, METHODS OF MAKING SAME, AND USES THEREOF | PTGES, PTGFR, PTGIS | NR1H2 1369/4885NR1H3 1430/4885DAO 1526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.